What are pharmaceutical intermediates

Pharmaceutical intermediates are some chemical raw materials or chemical products used in the process of pharmaceutical synthesis.

With the improvement of China's food and drug regulatory system, foreign-funded pharmaceutical enterprises will increasingly be unable to exercise the "green light privilege" in their business development in China as in the past, which means that foreign-funded pharmaceutical enterprises will also "queue up" according to the rules in the process of applying for pre clinical filing or approval in China.

Research prediction: all this also indicates that China's ethnic medicine industry is ushering in an unprecedented and fleeting short "opportunity period". China's pharmaceutical industry must seize this historic opportunity to change the situation that China's pharmaceutical R & D enterprises are broad but not specialized and production enterprises are large but not strong. It is expected that pharmaceutical R & D and production will achieve two strategic goals at the same time in the next eight years: 1 Generic drugs catch up with India; 2. Innovative drugs shorten the gap with developed countries in Europe and the United States, and even partially catch up. Create preconditions and create stability for comprehensively catching up when the time is ripe.

Macklin's strategic conception and Countermeasures

In order to seize this historical opportunity and assist the great rejuvenation of the national pharmaceutical industry. Macklin has been committed to building a national reagent brand and providing strong logistical support for the Chinese national pharmaceutical industry. At the same time, the latest information in the fields of pharmaceutical research, production and chemical industry in the world is widely collected to provide flanking cover for China's pharmaceutical research and development, technological innovation, large-scale production units, departments and enterprises.

We have collected the product information, synthetic routes and corresponding pharmaceutical intermediates of about 170 "patent cliff" APIs and some popular APIs, hoping to promote the development of generic drugs in China and the world.